Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new study conducted by researchers at the Kennedy Institute of Rheumatology has uncovered a pivotal role of asparagine metabolism in regulating B cell homeostasis and immune response.

GC B cell © Zhi Yi Wong

Germinal centre (GC) B cells are important for establishing immune defence. Despite having some of the highest proliferation rates among mammalian cells, their metabolism remains unusual and not fully understood. A team from the Kennedy Institute and collaborators has shed light on this critical process.

The findings, published as a research article in Science Immunology, identify the non-essential amino acid asparagine as a critical regulator of germinal centre (GC) B cell function, structures critical for refining antibodies to target infections effectively.

‘When asparagine is scarce, B cells struggle, leading to weakened GC B cell function’ said Yavuz Yazicioglu, KTPS DPhil student and first author of the study.

Reducing asparagine levels through diet or an asparagine-depleting drug, Asparaginase, weakened GC B cell function, leading to lower-quality antibody generation during flu infection, particularly from the cells with a defective capacity to produce asparagine.

‘We found when B cells were deprived of asparagine, they had reduced mitochondrial activity and building blocks such as nucleotides, suggesting asparagine sustains important metabolic processes in B cells,’ said Alex Clarke, Wellcome Trust Clinical Research Career Development Fellow. Alex further commented on the significance of their findings: ‘Our work highlights asparagine metabolism as a metabolic vulnerability in B cells that can be targeted to tackle diseases such as autoimmunity or malignancies with abnormal B cell immune responses.’

The study was funded by the Wellcome Trust, Cancer Research UK, and Versus Arthritis.

Similar stories

ImmunoKnight: Armoured Immune Cells for the Non-Surgical Treatment of Parkinson’s Disease

Researchers from the Kennedy Institute and others from the UK and Switzerland are exploring whether engineered immune cells could carry tiny, remote-controlled droplets into brain regions affected by Parkinson’s disease.

Could the gut’s nervous system hold new clues to treating Crohn’s disease?

Researchers at the Kennedy Institute are investigating whether the nervous system within the gut could provide a new way to understand and ultimately treat Crohn’s disease.

Oxford EMCRF starts pioneering engineered nTreg trial for severe autoimmune disease

The Oxford Experimental Medicine Clinical Research Facility (EMCRF) has recruited its first patients into the CHILL trial, an early-phase study of an innovative cell therapy for severe autoimmune disease.

First clinical study in GSK-Oxford Experimental Medicine Collaboration starts as first patient dosed in ulcerative colitis experimental trial

The first patient in the PEGASUS clinical study, part of the GSK-University of Oxford Experimental Medicine Collaboration, received the first dose last week, on 8th October 2026.

Arthritis origins may begin before birth, study finds

Researchers at the Kennedy Institute have discovered that some joints may be more susceptible to inflammatory arthritis before birth, offering new insight into why rheumatoid arthritis attacks particular joints while sparing others.

Researchers uncover hidden mechanism behind a major cancer therapy target

Kennedy researchers have revealed how one of the immune system's most important regulatory pathways operates at the earliest moments of T cell activation, providing new insights that could help improve cancer immunotherapy.